NCT00907738View on ClinicalTrials.gov

A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Advanced Cancer
Interventions
DRUG

vorinostat

All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00907738 - A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007) | Biotech Hunter | Biotech Hunter